Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

iCAALL - International Collaboration in Asthma, Allergy and Immunology

Hundreds of millions of people in the world suffer from allergies, and it is estimated that 300 million have asthma.* Inadequate or improper diagnosis and treatment of these chronic diseases and of immunodeficiency disorders results in lost productivity and substantial medical and socioeconomic burdens throughout the world.

Recognizing a lack of consensus-driven information and general recommendations, four of the most influential allergy/immunology professional organizations have joined forces to launch the International Collaboration in Asthma, Allergy and Immunology (iCAALL). Participating in iCAALL are the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI), the European Academy of Allergy and Clinical Immunology (EAACI) and the World Allergy Organization (WAO).

iCAALL is designed to collect and disseminate consensus-driven information about allergies, asthma and immunological diseases. Communicating this knowledge can positively impact diagnosis and treatment, as well as cost containment and policy decisions.

A major focus of this initiative is the production of a series of International Consensus (ICON) reports. These documents offer general recommendations based on global challenges in caring for patients with allergic and immunologic diseases.

View the iCAALL editorial that was published in the WAO Journal.

*Statistic source: World Health Organization

ICON on Food Allergy

This premier ICON was launched during the Annual Meeting of the American Academy of Allergy and Clinical Immunology (AAAAI) in Orlando (March 2012).

This ICON is published in the Journal of Allergy and Clinical Immunology (JACI).

Click to read the document here.

ICON on Pediatric Asthma

The second ICON report was launched during the EAACI Congress 2012 in Geneva. The goal of the ICON on Pediatric Asthma is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on their differences, thus providing a concise reference. The Pediatric Asthma ICON provides advice for the best clinical practice in pediatric asthma management.

Prof. Nikos Papadopoulus, EAACI Secretary General and Pediatric Asthma ICON Chair said: “Despite available treatments, less than 50% of asthmatic children control their symptoms”. “Pediatric asthma is a chronic disease and therefore, requires chronic treatment. With this Consensus we highlight that pediatric asthma can be controlled by establishing a partnership between patient and doctor and adhering to a well-designed personal management plan. Regular monitoring ascertains the effectiveness and fine-tunes treatment."

The Pediatric Asthma ICON is published in Allergy, the European Journal of Allergy and Clinical Immunology.

Click to read the document here.

ICON on Drug Allergy

Drug hypersensitivity reactions (DHRs) comprise all drug reactions resembling allergy. DHRs constitute 15% of all adverse drug reactions affecting more than 7% of the general population. DHRs can be allergic or non-allergic with immunologically-mediated DHRs being named drug allergies. They are typically unpredictable, necessitate treatment changes and can potentially be life-threatening. A definitive diagnosis enabling the institution of adequate treatment options and proper preventive measures typically requires a complete drug allergy work up.

Several guidelines and consensus statements on general or specific drug class-induced DHRs are available to support medical decisions on drug allergy; however, a standardized systematic approach for the diagnosis and management of DHRs is still a major challenge. The purpose of this document is to:

• highlight the key messages that are common to many existing guidelines
• critically review and comment on differences, thus providing a concise reference

Click to read the document here.

ICON on Hereditary and Acquired Angiodema

The ICON on Hereditary and Acquired Angioedema was released during the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, California (9 November 2012).

“There is an international lack of understanding, consensus-driven information and general recommendations for angioedema,” said David M. Lang, MD, chair of the ICON Hereditary and Acquired Angioedema and ACAAI Fellow. “This ICON report will help ensure the proper diagnosis and management of all forms of angioedema, while helping patients find relief and live healthy, active lifestyles.”

This ICON is published on Annals of Allergy, Asthma and Immunology.

Click to read the document here.

ICON on Eosinophil Disorders

The ICON on Eosinophil Disorders was released during the 2nd WAO International Scientific Conference (WISC 2012) in Hyderabad, India (7 December 2012).

“Although scientific achievements in the field of eosinophilic disorders have led to improved diagnosis and therapy for patients, a global consensus has been needed,” said Lanny J. Rosenwasser, M.D., chair of the ICON on Eosinophil Disorders. “The ICON provides a diagnostic algorithm, along with redefined criteria, terminologies and classifications of eosinophilic disorders, based on the latest developments published in the field and the work of individuals and groups focused on explaining the complexities of eosinophilic disorders. The report will aid physicians in providing treatment for patients that is targeted to the specific type of eosinophilic disorder. It also identifies several unmet needs in this disease area that need to continue to be addressed in a multi-disciplinary way.”

The full report is published in the December 2012 issue of the World Allergy Organization Journal

Click to read the document here.